focus -WSS

focus

author：entertainment 2025-10-04 11:56:25 Page View：9714

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Kidney transplant patients stopped immunosuppressants in trial
Next article： In Memoriam: Notable people who died in 2023

knowledge

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

How to convince healthy people to buy insurance

Adobe’Tistheseason—openenrollmentseason,thatis.SincebeforetheNov.1 starttotheannualopenenrollmentper

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Gene therapy’s promise and the high cost of hope

AdobeAtthebustlingChicagoO’Hareairport,myluggageandIcollidedwithanelderlycouple.MyheartsankwhenIreal

focus

explore

knowledge

Gene therapy’s promise and the high cost of hope